资料显示，华仁药业股份有限公司位于山东省青岛市高科技工业园株洲路187号，成立日期1998年5月20 日，上市日期2010年8月25日，公司主营业务涉及大输液(包括非PVC软袋、直立式软袋、塑瓶、玻瓶大 输液)、腹膜透析液、呼吸科用药、精麻科用药以及原料药、配套医药包材、医疗器械、大健康产品。 主营业务收入构成为：基础输液40.63%，腹透液34.90%，治疗制剂14.92%，医疗器械8.14%，其他 1.41%。 截至11月10日，华仁药业股东户数4.01万，较上期减少1.23%；人均流通股29447股，较上期增加 1.25%。2025年1月-9月，华仁药业实现营业收入9.76亿元，同比减少9.07%；归母净利润5457.98万元， 同比减少42.87%。 11月17日，华仁药业涨0.00%，成交额7944.32万元。两融数据显示，当日华仁药业获融资买入额408.32 万元，融资偿还637.98万元，融资净买入-229.66万元。截至11月17日，华仁药业融资融券余额合计2.34 亿元。 融资方面，华仁药业当日融资买入408.32万元。当前融资余额2.34亿元，占流通市值的5.46%，融资余 额低于近一年5 ...

Group 1 - Duopule plans to reduce its shareholding by no more than 1%, amounting to a maximum of 619,000 shares [1] - Lideman intends to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, focusing on tuberculosis screening and diagnosis [2] - Huahuan Group is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - Dongbai Group clarifies it does not engage in duty-free business, maintaining normal operations [4][5] - Changsheng Bearing's actual controller plans to reduce holdings by up to 1.99%, equating to 5.94 million shares [6][7] - Jidian plans to invest 5.698 billion yuan in the Baicheng Phase II coal power project, a key initiative under the national "14th Five-Year Plan" [9][10] Group 3 - Baoneng New Energy reports completion of land-based works for the expansion of the Lufeng Qiaohai Bay Power Plant [11][12] - Changshu Bank proposes to appoint Lu Dingchang as the new president and chief compliance officer [13][14] - Kangqiang Electronics plans to reduce its shareholding by no more than 1%, totaling up to 3.7526 million shares [14] Group 4 - Jilin Chemical Fiber intends to reduce its holdings by up to 2%, equating to 49.1774 million shares [15][16] - CanSino's inhaled tuberculosis vaccine has commenced Phase I clinical trials in Indonesia [17][18] - ST Dongyi's stock has been suspended for review due to significant price fluctuations [19] Group 5 - ST Yatai plans to reduce its holdings by up to 1.98%, totaling 6.4 million shares [20] - Huaren Pharmaceutical intends to reduce its holdings by up to 3%, equating to 35.4663 million shares [21] - Jianglong Shipbuilding's controlling shareholder plans to reduce holdings by up to 2%, amounting to 7.5534 million shares [22] Group 6 - Borui Pharmaceutical's BGM1812 injection has received approval for clinical trials targeting overweight or obesity [23][24] - ST Zhongzhu announces the transfer of 10.38% of its shares, totaling approximately 403 million yuan [25][26] - Shenzhou Digital plans to establish an employee stock ownership plan with a maximum fundraising of 360 million yuan [27][28] Group 7 - Kaichuang Electric plans to establish a joint research center with Tsinghua University, focusing on embodied intelligence [29] - Daming City intends to acquire 19.43% of Baicaibang for 694 million yuan, specializing in communication solutions [29]

Core Points - Dongbai Group does not have duty-free operating qualifications and is not involved in the operation of duty-free goods [1] - Sanyuan Co., Ltd. launched a seasonal product, milk skin candy hawthorn, which has a very small revenue scale due to its short sales period [1] - Jidian Co., Ltd. plans to invest in the construction of a coal power project with a capacity of 2×660,000 kilowatts [1] - Anhui Construction's subsidiary won contracts totaling 1.753 billion yuan [1] - Guotai Group intends to acquire 100% equity of Beikuan Explosive for 110 million yuan [1] - Yongji Co., Ltd. has completed a buyback of 1.25% of its shares [1] - Changsheng Bearing's actual controller's concerted actor plans to reduce holdings by no more than 1.99% [1][2] - Lichung Group has received project designation from clients [1][2] - Hefei China may apply for a trading suspension if its stock price continues to rise abnormally [1][2]

Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics and investor sentiment in the A-share market [1] Shareholder Reductions - *ST Yitai: Taihua Investment plans to reduce its stake by up to 1.9798% [1] - Huaren Pharmaceutical: Huaren Century Group intends to reduce its stake by no more than 3% [1] - Jianglong Shipbuilding: Controlling shareholder Yan Zhiqing plans to reduce his stake by up to 2% [1] - Jujie Microfiber: Controlling shareholder plans to reduce its stake by no more than 2% [1] - Wangsu Technology: Director Liu Chengyan plans to reduce his stake by up to 1% [1] - Haineng Industry: Zhou Hongjun plans to reduce his stake by up to 3% [1] - Changsheng Bearing: A concerted action by the actual controller plans to reduce its stake by up to 1.99% [1] - Jilin Chemical Fiber: Fangda Investment plans to reduce its stake by up to 2% [1] - Kangqiang Electronics: Simais plans to reduce its stake by up to 1% [1] - Pangu Intelligent: Shareholders holding over 5% plan to reduce their stake by up to 1% [1] - Changlian Technology: Fuhai New Materials plans to reduce its stake by up to 2% [1] - Xiongshi Technology: Some directors and senior management plan to reduce their stake by up to 0.17% [1] - Ruixin Technology: Shanghai Guoshi and its concerted actions have cumulatively reduced their stake by 2.97% [1] Other Notable Events - Tongde Chemical: Wholly-owned subsidiary Tongde Kexin has been listed as a dishonest executor [1] - Kangda New Materials: Terminated plans to acquire equity in Beiyi Semiconductor [1]

公告显示，截至公告披露日，华仁世纪集团持有公司股份8154.3万股，占公司总股本的6.9%。拟减持的 原因为华仁世纪集团自身经营需要。 北京商报讯(记者丁宁)11月13日晚间，华仁药业（300110）发布公告称，公司持股5%以上股东华仁世纪 集团有限公司(以下简称"华仁世纪集团")计划自减持计划公告之日起十五个交易日后的三个月内通过集 中竞价交易方式、大宗交易方式减持不超过公司总股本3%的股份，即不超过3546.63万股。 ...

华仁药业（300110）(300110.SZ)发布公告，公司于近日收到持股5%以上股东华仁世纪集团有限公司(简 称"华仁世纪集团")《关于减持华仁药业股份计划的告知函》，华仁世纪集团计划自减持计划公告之日 起十五个交易日后的三个月内通过集中竞价交易方式、大宗交易方式减持不超过公司总股本3%的股 份，即不超过3546.63万股。 ...

智通财经APP讯，华仁药业(300110.SZ)发布公告，公司于近日收到持股5%以上股东华仁世纪集团有限 公司(简称"华仁世纪集团")《关于减持华仁药业股份计划的告知函》，华仁世纪集团计划自减持计划公 告之日起十五个交易日后的三个月内通过集中竞价交易方式、大宗交易方式减持不超过公司总股本3% 的股份，即不超过3546.63万股。 ...

截至发稿，华仁药业市值为43亿元。 每经头条（nbdtoutiao）——"银行直供房，不计成本卖！"有的半价出售，众多刚需还不知道！银行用 过的房很抢手，有人加价100万元抢拍 （记者 王瀚黎） 每经AI快讯，华仁药业（SZ 300110，收盘价：3.62元）11月13日晚间发布公告称，华仁药业股份有限 公司于近日收到持股5%以上股东华仁世纪集团有限公司《关于减持华仁药业股份计划的告知函》，华 仁世纪集团计划自减持计划公告之日起十五个交易日后的三个月内通过集中竞价交易方式、大宗交易方 式减持不超过公司总股本3%的股份，即不超过约3547万股。 2025年1至6月份，华仁药业的营业收入构成为：医药工业占比95.79%，医药商业占比4.21%。 ...

人民财讯11月13日电，华仁药业（300110）11月13日公告，公司持股6.9%的股东华仁世纪集团拟减持不 超过公司总股本3%的股份，即不超过3546.63万股。 ...

【华仁药业：股东华仁世纪集团拟减持不超过总股本3%的股份】智通财经11月13日电，华仁药业 (300110.SZ)公告称，公司收到持股5%以上股东华仁世纪集团的减持计划告知函，华仁世纪集团计划自 减持计划公告之日起十五个交易日后的三个月内，通过集中竞价交易方式、大宗交易方式减持不超过公 司总股本3%的股份，即不超过3546万股。减持原因为自身经营需要，减持价格将根据市场价格确定。 转自：智通财经 ...